SENETEK PLC ANNOUNCES THE LAUNCH OF INVICORP® IN DENMARK
NAPA, California, December 19, 2006 -- Senetek PLC (OTCBB:SNTKY), www.senetekplc.com, a life sciences product development company targeting the science of aging to include skincare and dermatological therapeutics, erectile dysfunction, nutrition and cancer, announced today that the Company's marketing partner for Europe has launched Invicorp® in Denmark. Invicorp® is the Company's proprietary treatment for erectile dysfunction. It is estimated that 52% of men over the age of 40 suffer at some time from erectile dysfunction (ED) and many of them are unsuitable for treatment with existing oral therapies. Invicorp®, a local injectable treatment, is expected to treat those patients who need drug therapy for ED but are contraindicated for oral phosphodiesterase (PDE) inhibitors such as Viagra®, Levitra® and Cialis®. "Thirty percent of males afflicted with ED do not respond to oral drugs, another 15% reveal contraindications to currently available therapy, and a subset of patients actually prefer injection therapy due to its predictable short time-to-onset of erection and reliable rigidity compared to oral drugs.1"
"The launch of Invicorp in Denmark is a major achievement and validates another successful step in the execution of the Company's business plan which targets the commercialization of one new product per year," stated Frank Massino, Senetek Chairman and Chief Executive Officer. "We look forward to Invicorp's success in Denmark and to commercialization in other EU nations beginning in 2007."
